QRC-PVD Clinical Trial - Telmisartan in the Management of Abdominal Aortic Aneurysm (TEDY)

This study aimed to see whether a medication, Telmisartan, can reduce the growth of small (35-49cm) abdominal aortic aneurysms (AAA).

Background

The only treatment available for AAA is surgical repair. Surgery is associated with a number of complications and is only performed on patients who have a high risk of bursting their AAA. Abdominal aortic aneurysms slowly grow over time and at the commencement of this study, there were no current pharmaceuticals which slowed their growth.

Consenting participants (230) attended our study centres a minimum of 7 times over 24 months as part of this study, which took place over six years.

Outcomes

The data collected from this study is still being analysed. Results will be published in peer-reviewed journal articles and communicated to participants.

See also:

Morris, D. et al. (2015) TElmisartan in the management of abDominal aortic aneurYsm (TEDY): the study protocol for a randomised controlled trial. Trials, 16:274 [doi:10.1186/s13063-015-0793-z]